EUVIMEDEUVIMED entdecken
Open Access

Comparison of Early-, Average-, and Late-Onset Pancreatic Cancer in a Multi-Site Cancer Center: Treatment Patterns and Outcomes

Chirag K Patel, Jimmy J Hwang, Mohamed E Salem, Kunal C Kadakia

Journal of Patient-Centered Research and Reviews · 12.05.2026 · 13 (2) · 65-75

DOI: 10.17294/2330-0698.2191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Patient-Centered Research and Reviews, online erschienen am 12.05.2026. Verfasst von Chirag K Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Solid Tumor Oncology, Levine Center, Atrium Health, Charlotte, NC. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to investigate treatment and outcomes differences, as well as predictors of early mortality, among early-onset pancreatic adenocarcinoma (EOPC, ≤ 50 years), average-onset pancreatic adenocarcinoma (AOPC, 51-69 years), and late-onset pancreatic adenocarcinoma (LOPC, ≥ 70 years).

Methods

We retrospectively analyzed 333 patients with pancreatic adenocarcinoma at a multi-site center between 2011-2018. Clinical, demographic, and treatment variables were compared by age group. Predictors of early mortality (death ≤ 6 months from diagnosis) were assessed using multivariable logistic regression. Survival outcomes were evaluated using Kaplan-Meier analyses.

Results

Among the 333 patients, 56% were male, and the mean age was 61.5 years. EOPC patients had higher rates of tobacco use (68% vs 54%, p = 0.0094) and higher histological grade (57% vs, 41%, p = 0.048) than older cohorts. In non-metastatic patients, EOPC patients were more likely to undergo curative intent surgery (70% vs 38%, p ≤ 0.0001) and receive adjuvant radiation (40% vs 15%, p = 0.002). Early mortality occurred in 28% of non-metastatic and 59% of metastatic patients, with lower rates in EOPC. Predictors of early mortality included older age, higher neutrophil-to-lymphocyte ratio, lack of surgery, and absence of radiation therapy in univariable analysis; however, none of these factors remained significant in multivariable analysis. Median survival was 11.1 months in EOPC, 8.7 months in AOPC, and 4.3 months in LOPC.

Conclusions

EOPC patients demonstrate better survival and receive more treatments than older cohorts. Despite these differences, PC outcomes remain poor across all groups. Further research is warranted to validate early mortality predictors and inflammatory biomarkers in EOPC.

Schlagwörter

Stichwörter der Autor:innen

early-onsetpancreatic cancerpancreatic neoplasmsprognosistreatment outcomes

Autor:innen und Institutionen

  • Department of Solid Tumor Oncology, Levine Center, Atrium Health, Charlotte, NC.
  • Department of Supportive Oncology, Levine Center, Atrium Health, Charlotte, NC.

Zitieren

APA

Patel, C. K., Hwang, J. J., Salem, M. E., & Kadakia, K. C. (2026). Comparison of Early-, Average-, and Late-Onset Pancreatic Cancer in a Multi-Site Cancer Center: Treatment Patterns and Outcomes. Journal of Patient-Centered Research and Reviews, 13(2), 65-75. https://doi.org/10.17294/2330-0698.2191

Vancouver

Patel CK, Hwang JJ, Salem ME, Kadakia KC. Comparison of Early-, Average-, and Late-Onset Pancreatic Cancer in a Multi-Site Cancer Center: Treatment Patterns and Outcomes. Journal of Patient-Centered Research and Reviews. 2026;13(2):65-75. doi:10.17294/2330-0698.2191

BibTeX
@article{Patel2026,
  author = {Patel, Chirag K and Hwang, Jimmy J and Salem, Mohamed E and Kadakia, Kunal C},
  title = {Comparison of Early-, Average-, and Late-Onset Pancreatic Cancer in a Multi-Site Cancer Center: Treatment Patterns and Outcomes},
  journal = {Journal of Patient-Centered Research and Reviews},
  year = {2026},
  volume = {13},
  number = {2},
  pages = {65--75},
  doi = {10.17294/2330-0698.2191}
}
Kostenlos starten →